Distinguishing Benign and Malignant Ovarian Tumors Preoperatively

Gatot Nyarumenteng Adhipurnawan Winarno


Abstract


Ovarian cancer ranks as the fifth leading cause of cancer-related mortality among women globally. In 2020, there were approximately 314,000 reported cases of new ovarian cancer patients, resulting in an estimated 207,000 deaths.1 The highest incidence rates were observed in non-Hispanic white women, with 12.0 cases per 100,000 individuals, followed by Hispanics (10.3 per 100,000), non-Hispanic blacks (9.4 per 100,000), and Asian/Pacific Islander women (9.2 per 100,000). Disparities in access to healthcare services and treatment modalities contribute to varied mortality patterns, with the highest rates recorded among African populations. In Indonesia, ovarian cancer ranks as the third most prevalent cancer, comprising 7.84% of total cancers diagnosed in women.1 The heightened mortality rate observed in ovarian cancer can be ascribed to several factors including asymptomatic tumor growth, delayed manifestation of symptoms, and inadequate screening methods, ultimately resulting in diagnoses at advanced stages. Consequently, ovarian cancer is frequently described as a “silent killer”.2 To address diagnostic delays and reduce mortality rates associated with ovarian cancer, early detection and differentiation between benign and malignant ovarian tumors are crucial. This requires a comprehensive assessment comprising patient history, physical examination, and supporting investigation.

Keywords


Malignant, Ovarian, Tumors, Cancer

Full Text:

PDF

References


Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. International journal of cancer. 2021;149(4):778-89.

Harsono AB. Kanker Ovarium:“The Silent Killer”. Indonesian Journal of Obstetrics & Gynecology Science. 2020;3(1):1-6.

Salima S, Rachmawati A, Harsono AB, Erfiandi F, Fauzi H, Prasekti H, et al. Ovarian Cancer-Self Assessment: An Innovation for Early Detection and Risk Assessment of Ovarian Cancer. Asian Pacific Journal of Cancer Prevention: APJCP. 2022;23(8):2643.

Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007;109(2):221-7.

Mathieu KB, Bedi DG, Thrower SL, Qayyum A, Bast Jr RC. Screening for ovarian cancer: imaging challenges and opportunities for improvement. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2018;51(3):293.

Winarno GNA, Mulyantari AI, Kurniadi A, Suardi D, Zulvayanti Z, Trianasari N. Predicting Chemotherapy Resistance in Gestational Trophoblastic Neoplasia: Ratio of Neutrophils, Lymphocytes, Monocytes, and Platelets. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2022;28:e938499-1.

Iyer VR, Lee SI. MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. American Journal of Roentgenology. 2010;194(2):311-21.

Kovács AR, Sulina A, Kovács KS, Lukács L, Török P, Lampé R. Prognostic significance of preoperative NLR, MLR, and PLR values in predicting the outcome of primary cytoreductive surgery in serous epithelial ovarian cancer. Diagnostics. 2023;13(13):2268

Yin X, Wu L, Yang H, Yang H. Prognostic significance of neutrophil–lymphocyte ratio (NLR) in patients with ovarian cancer: A systematic review and meta-analysis. Medicine. 2019;98(45).

Bast R, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. The Journal of clinical investigation. 1981;68(5):1331-7.

Zhang R, Siu MK, Ngan HY, Chan KK. Molecular biomarkers for the early detection of ovarian cancer. International Journal of Molecular Sciences. 2022;23(19):12041.

Chen Y, Wang S, Liu T, Wu Y, Li J-L, Li M. WAP four-disulfide core domain protein 2 gene (WFDC2) is a target of estrogen in ovarian cancer cells. Journal of ovarian research. 2016;9(1):1-11.

Hidayat YM, Winarno GNA, Tobing MDL, Kustiandi A, Mantilidewi KI, Krisnadi SR. The Role of Akt2 and CA-125 Serum Levels as Predictors for Successful Cytoreduction in Epithelial Ovarian Cancer Surgery. European Journal of Gynaecological Oncology. 2020;41(5):739-44.

Chhikara N, Saraswat M, Tomar AK, Dey S, Singh S, Yadav S. Human epididymis protein-4 (HE-4): a novel cross-class protease inhibitor. PLoS One. 2012;7(11):e47672.

Yanaranop M, Jantarateptewan N, Tiyayon J, Nakrangsee S. Significance of serum human epididymis protein 4 and cancer antigen 125 in distinguishing type I and type II epithelial ovarian cancers. International Journal of Gynecologic Cancer. 2018;28(6).

Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Abd-Alla AA, Ghaffar HMA. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Diagnostic pathology. 2013;8:1-8.

Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. Journal of ovarian research. 2019;12:1-9.

Ferraro S, Borille S, Caruso S, Boggio A, Muzio F, Rizzi A, et al. Body mass index does not influence human epididymis protein 4 concentrations in serum. Clinica chimica acta; international journal of clinical chemistry. 2015;446:163-4

Vallen MJ, van der Steen SC, van Tilborg AA, Massuger LF, van Kuppevelt TH. Sulfated sugars in the extracellular matrix orchestrate ovarian cancer development:‘When sweet turns sour’. Gynecologic oncology. 2014;135(2):371-81.

Afratis N, Gialeli C, Nikitovic D, Tsegenidis T, Karousou E, Theocharis AD, et al. Glycosaminoglycans: key players in cancer cell biology and treatment. The FEBS journal. 2012;279(7):1177-97.

Kenny PA, Bissell MJ. Tumor reversion: correction of malignant behavior by microenvironmental cues. International journal of cancer. 2003;107(5):688-95.

Labiche A, Heutte N, Herlin P, Chasle J, Gauduchon P, Elie N. Stromal compartment as a survival prognostic factor in advanced ovarian carcinoma. International Journal of Gynecologic Cancer. 2010;20(1).

Ten Dam GB, Van De Westerlo EM, Purushothaman A, Stan RV, Bulten J, Sweep FC, et al. Antibody GD3G7 selected against embryonic glycosaminoglycans defines chondroitin sulfate-E domains highly up-regulated in ovarian cancer and involved in vascular endothelial growth factor binding. The American journal of pathology. 2007;171(4):1324-33




DOI: http://dx.doi.org/10.24198/obgynia.v7i2.683

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.


     
     

Creative Commons License
Indonesian Journal of Obstetrics & Gynecology Science is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License
  Web Analytics
  View My Stat